The abstract is read at the publisher; the summary is JClub's.
In the CARDIO-TTRansform phase 3 trial for transthyretin amyloid cardiomyopathy, baseline TTR stabilizer use strongly modified eplontersen’s effect (P interaction=0.017).
- Why it matters: It is unclear whether adding a TTR gene silencer to background TTR stabilizers helps, and whether silencer effects differ when stabilizers are not used.
- What they did: In 1,432 randomized patients treated with eplontersen 45 mg every 4 weeks or placebo for up to 140 weeks, investigators prespecified an analysis by baseline stabilizer use (57% on stabilizers).
- The result: Eplontersen reduced the primary composite endpoint only in patients not on stabilizers at baseline (RR=0.71, 95% CI 0.54 to 0.93, P=0.012), not in those on stabilizers (RR=1.14, 95% CI 0.85 to 1.53, P=0.39), with a favorable safety profile in both groups.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.